

# Therapy of type 1 diabetes with T regulatory cells and anti-CD20 monoclonal antibody

<b>Submission date</b> 19/01/2021	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 22/01/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 05/05/2022	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Type 1 diabetes is a disease which usually develops in patients as a result of the destruction of the pancreas – the internal organ producing insulin. No insulin in the body results in high levels of sugar glucose in the blood. This can lead to impaired consciousness leading to coma, excessive drinking and urination, and weight loss. In the long term, diabetes is responsible for damage to the kidneys, eyes and heart. Current medicine is able to find early symptoms suggesting the beginning of diabetes or increased risk of the onset. The level of anti-islet antibodies and HLA antigens can be used for such a purpose. Usually, those anti-islet antibodies and some specific forms of HLA antigens can be found in patients with diabetes.

Currently, it is known that the disease is triggered by cells called lymphocytes, which attack and kill pancreatic insulin-producing cells. It is also known that the destruction of the pancreas is facilitated by the lack of some other cells, T regulatory cells. T regulatory cells are able to stop lymphocytes from killing pancreatic cells but this effect requires a high number of the former cells. Unfortunately, the number of T regulatory cells in blood is very low. It is estimated that one T regulatory cell can be found in a million of other blood cells and that they are even rarer in patients with diabetes.

The study aims to assess the safety and effectiveness of treatment with T regulatory cells and anti-CD20 monoclonal antibodies and to address the questions: 'how safe is the treatment?', 'how far we can delay the onset of full onset type 1 diabetes?', 'how much of the insulin secretion can be saved from type 1 diabetes?'.

### Who can participate?

Patients aged 8-16, up to 2 months after being diagnosed with type 1 diabetes

### What does the study involve?

Patients are randomly allocated to receive doses of T regulatory cells with or without the anti-CD20 antibody rituximab, or to a treatment-free control group.

A sample of blood is taken from the patients and T regulatory cells are separated from it. Then, the number of these cells will be increased in the laboratory. If the number of T regulatory cells is increased sufficiently, they are administered as an accessory treatment of diabetes. Before the administration, the cells are carefully checked for safety and quality. This is experimental therapy which was previously used from 2008 and for treating patients with type 1 diabetes

from 2010. Up to now, the researchers have not seen any health problems in patients treated with these cells. Nevertheless, for safety the patients will be under special medical care during the blood drawing and infusion of T regulatory cells and will be regularly examined. In addition to the preparation of regulatory cells, patients will also receive a drug (at intervals of several days) containing antibodies. The aim of this medicine is to destroy some of the white blood cells that are involved in pancreatic damage and the development of diabetes. Administration of this drug is intended to enhance the function of regulatory cells. This drug has already been successfully used in the treatment of type 1 diabetes. Administration of the drug will be performed in the operating room under medical supervision. The drug will be administered into a vein. Then, the patients will be followed up for 2 years in order to assess the safety and effectiveness of the treatment.

What are the possible benefits and risks of participating?

In previous studies, patients receiving the treatment had a significantly longer time without the need to receive insulin, and in cases where they needed insulin the doses of the drug were lower. However, it should be emphasized that the proposed treatment is experimental and the patient's health condition may not improve or even deteriorate as a result of adverse effects. Treatment with T regulatory cells has been used since 2008 and in the treatment of diabetes since 2010. So far, among the side effects of the treatment, the researchers have observed only a few viral infections lasting less than 7 days, which gave way without any consequences. The blood donation and the administration of T regulatory cells may be theoretically associated with the occurrence of adverse effects typical of peripheral vascular punctures and transfusions. These are mainly excessive bleeding, reactions related to the site of injection, fever, chills, petechiae and other skin changes. Diagnosis and treatment of these reactions will belong to the physician assisting with the procedures.

Regulatory lymphocytes suppress immune reactions and therefore potentially can increase sensitivity to serious infections and promote the growth of cancer cells present in the patient's body. These symptoms after administration of regulatory lymphocytes have never been described (the longest observation of the patient after administration of these cells is more than 5 years), but because of their theoretically possible occurrence, this statement must be included in this information.

The manufacturer of the anti-CD20 antibody lists the following adverse effects: bacterial and viral infections, upper respiratory tract infections, bronchitis, urinary tract infections, neutropenia, leukopenia, febrile neutropenia, thrombocytopenia, infusion reactions (mainly fever, chills and cold feeling), angioedema edema, nausea, pruritus, rash, alopecia, fever, chills, asthenia, headache and lowered IgG antibodies.

During the first 2 hours during the first infusion the following may occur: fever, chills and a feeling of cold. There is less frequent: pain at the injection site, blisters on the skin, pruritus, nausea, tiredness, headache, difficulty in breathing, swelling of the tongue or throat, runny nose or itching, vomiting, hot flush or palpitations, heart attack or lowering the number of platelets. People who have had heart disease or angina before treatment may get worse. There is a reduced probability occurring of these reactions after the second infusion.

Exceptionally, rare neurological complications called progressive multifocal leukoencephalopathy may occur. Due to the mechanism of action, rituximab may increase the risk of cancer. Based on the limited experience of using rituximab in rheumatoid arthritis (an autoimmune disease with a similar mechanism to type 1 diabetes), it seems that the data currently available do not support the increased risk of cancer, but theoretically there is a risk cannot be excluded.

Each patient undergoing treatment will be subject to constant medical supervision in order to minimize/avoid the effects of potential adverse effects. The basic monitoring will be carried out during control visits resulting from the study schedule. In urgent cases, parents, carers or

patients will have the opportunity to telephone and have personal contact with the attending physician/researcher.

Where is the study run from?  
Medical University of Gdańsk (Poland)

When is the study starting and how long is it expected to run for?  
February 2013 to December 2019

Who is funding the study?  
1. National Centre for Research and Development (Poland)  
2. EU Framework Programme Horizon 2020

Who is the main contact?  
Piotr Trzonkowski MD PhD  
ptrzon@gumed.edu.pl

**Study website**  
[http://serwer1531749.home.pl/strategmed/sm/StrategmedBackup/public\\_html/tregvac/](http://serwer1531749.home.pl/strategmed/sm/StrategmedBackup/public_html/tregvac/)

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Piotr Trzonkowski

**ORCID ID**  
<https://orcid.org/0000-0001-5287-5210>

**Contact details**  
Medical University of Gdansk  
Department of Medical Immunology  
Debinki 7  
Gdańsk  
Poland  
80-952  
+48 (0)58 3591593  
ptrzon@gumed.edu.pl

## Additional identifiers

**EudraCT/CTIS number**  
2014-004319-35

**IRAS number**

**ClinicalTrials.gov number**  
Nil known

## Secondary identifying numbers

NKBBN/374/2012-NKBBN/374- 7/2014, version 09\_2-14, dated 30-Sep-2014

# Study information

## Scientific Title

Therapy of type 1 diabetes with ex-vivo expanded CD4+CD25+CD127- T regulatory cells (Tregs) and anti-CD20 monoclonal antibody – a randomized trial

## Acronym

TregVAC 2.0

## Study objectives

Rationale: Type 1 diabetes is a condition in which pancreatic islets are destroyed by self-reactive effector T cells. The process is facilitated by deficits in the number and suppressive activity of T regulatory cells (Tregs). The administration of expanded autologous CD4+CD25+FoxP3+ Tregs in children and adolescents with recently diagnosed type 1 diabetes can delay the process of pancreatic islets destruction by suppressing self-reactive effector T cells. Early administration and repetitive doses of Tregs seem to positively affect this suppressive effect.

B lymphocytes seem also contribute to the pathogenesis of the disease as their selective depletion with the anti-CD20 antibody rituximab results in preserved beta-cell function in patients with type 1 diabetes of recent onset. Although clinically significant, the therapeutic effect of these two therapies is only transient, and patients eventually develop diabetes. In this study, these two therapeutic approaches are combined. Patients are recruited in earlier phases of the disease and treated by repetitive administration of Tregs and anti-CD20 antibody rituximab with the aim of significantly prolonging insulin independence and further delaying disease onset.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved 21/01/2014, Independent Bioethics Committee for Scientific Research at the Medical University of Gdańsk (Dębinki 7, 80-211, Gdańsk, Poland; +48 (0)58 349 25 05, +48 (0)58 349 10 11; irmez@gumed.edu.pl), ref: NKBBN / 374 / 2012 with correction NKBBN / 374-7 / 2014

## Study design

Prospective multicenter randomized open-label single-blinded placebo-controlled parallel-group study

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

## Treatment

### Participant information sheet

Polish version is available at [http://serwer1531749.home.pl/strategmed/sm/StrategmedBackup/public\\_html/tregvac/](http://serwer1531749.home.pl/strategmed/sm/StrategmedBackup/public_html/tregvac/)

### Health condition(s) or problem(s) studied

Type 1 diabetes

### Interventions

Randomization:

The patient receives a sequential number (1 to 45) and is randomized to one of the groups prior to blood collection for expansion according to a predefined bloc of numbers assigned to particular groups. Due to the specificity of study, the randomization is performed by the team separated from clinical investigators. For the same reason, the person responsible for randomization will not have access to the clinical and laboratory results collected by the team responsible for the clinical part of the study until the end of the study.

Two parallel groups and a treatment-free control arm (total N=45, Tregs group N=15, Tregs+anti-CD20 rituximab group N=15, treatment-free control group N=15).

Patients are randomized to receive doses of Tregs between 10 and 30 x 10<sup>6</sup>/kg (up to not more than 60 x 10<sup>6</sup> cells/kg in total) on day 0 and day 90. Those randomized to treatment with both Tregs and anti-CD20 antibody receive anti-CD20 antibody rituximab at 375 mg/m<sup>2</sup> on study days 14, 22, 29 and 36.

Duration of follow up: 24 months

### Intervention Type

Biological/Vaccine

### Phase

Phase I/II

### Drug/device/biological/vaccine name(s)

CD4+CD25+CD127- T regulatory cells (Tregs) preparation, rituximab

### Primary outcome measure

1. Number of adverse effects assessed from histories taken from patients, obtained during physical examination and laboratory tests at 2 years (week 104) after the first dose of Tregs
2. C-peptide level measured as fasted, post-MMTT stimulation and after glucagon test from peripheral blood at 2 years after the first dose of Tregs
3. Daily insulin dose per kg of body weight (DDI) assessed using patient records at 2 years after the first dose of Tregs
4. Number of treated patients in remission (the number of patients with daily insulin dose lower than 0.5U/kg/day and HbA1c lower than 6.5%) at 1 and 2 years after the first dose of Tregs

### Secondary outcome measures

1. The following four secondary safety endpoints are documented as AEs of special interest (AESI) and related treatment-emergent AEs (TEAEs), where appropriate, throughout 24 months follow-up:

- 1.1. Assessment of the occurrence and severity of side effects directly related to Tregs (hypersensitivity reactions, injection-site thromboembolic events) and blood sampling (>2 g/dl drop in hemoglobin levels)
- 1.2. Assessment of the occurrence and severity of effects directly related to anti-CD20 antibody rituximab administration (hypersensitivity reactions)
- 1.3. Assessment of the occurrence and severity of side effects associated with administration of Tregs or anti-CD20 rituximab antibodies, primarily immunosuppressive effects: occurrence of infections of any etiology and de novo tumors detected
- 1.4. Any serious AE (SAE) in two or more patients with a confirmed association with the administration of therapy
2. The efficacy is documented as:
  - 2.1. C-peptide level measured as fasted level from peripheral blood at weeks 2, 5, 12, 26, 39, 52, 65, 78, 92, and 104
  - 2.2. C-peptide level measured post MMTT stimulation and after glucagon test from peripheral blood at weeks 12, 26, 52, 78, and 104
  - 2.3. Exogenous insulin dose per kg of body weight assessed using patient records at weeks 2, 3, 4, 5, 12, 14, 26, 39, 52, 65, 78, 92, and 104
  - 2.4. The proportion of insulin-independent patients (DDI = 0 UI/kg body weight [b.w.]) assessed using patient records at weeks 52 and 104
  - 2.5. The proportion of patients in remission (DDI  $\leq$  0.5 UI/kg b.w. and HbA1c lower than 6.5%) assessed using patient records and laboratory tests at weeks 52 and 104
  - 2.6. HbA1c level (%) measured using patient records and laboratory tests at week 2, 5, 12, 26, 39, 52, 65, 78, 92, and 104
  - 2.7. Glycemic control (fasting average of 7 days) measured using patient records and laboratory tests at week 2, 5, 12, 26, 39, 52, 65, 78, 92, and 104
  - 2.8. The amount and intensity of side effects of therapy assessed from histories taken from patients, obtained during physical examination and laboratory tests at weeks 52 and 104
  - 2.9. Peripheral blood lymphocyte immunophenotype measured using flow cytometry tests at weeks 2, 5, 12, 14, 26, 39, 52, 65, 78, 92, and 104 with basic phenotype results

### **Overall study start date**

13/02/2013

### **Completion date**

31/12/2019

## **Eligibility**

### **Key inclusion criteria**

1. 8 to 16 years of age
2. BMI in the range of 25-75 percentiles (according to OLAF)
3. Fasting plasma C-peptide more than 0.7 ng/ml and in a stimulation test the increase is  $\geq$ 100%
4. The presence of anti-islet autoantibody (ICA, IAA, GAD) - high titer one of the antibodies ( $\geq$ 4 times the norm, not applicable ICA) or low titer of two or three antibodies (2-4 times the norm)
5. Ability to provide written informed consent by parents (and patients if above 16 years old)
6. Involvement of the patients and parents in the intensive diabetes management defined as self-monitoring of glucose values no less than three times per day and by the administration of insulin
7. Appropriate venous access for blood drawing

### **Participant type(s)**

Patient

**Age group**

Child

**Lower age limit**

8 Years

**Upper age limit**

16 Years

**Sex**

Both

**Target number of participants**

45 (randomization 1:1; Tregs group: 15 patients treated with Tregs; TregsCD20 group: 15 patients treated with Tregs and CD20 antibody; control group: 15 patients without treatment)

**Total final enrolment**

45

**Key exclusion criteria**

1. No agreement for participation in the study and no informed consent signed
2. Other than autoimmune type 1 diabetes
3. Age below 8 and above 16 years
4. IgA deficiency or other genetic defect present
5. BMI <25 or >75 percentiles for a particular age
6. Hypersensitivity to anti-CD20 or other components of the preparation
7. Presence or history of active infection including hepatitis B, hepatitis C, HIV, tuberculosis (TB) or syphilis. Subjects with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection
8. Presence of active EBV virus infection (positive IgM)
9. Presence or history of active systemic fungal infection
10. Any history of malignancy
11. Anemia, lymphopenia, neutropenia or thrombocytopenia below the lower limits of the reference range during the 6 weeks before study
12. Known hypercoagulable state
13. Medical treatment requiring chronic use of drugs other than insulin longer than 3 months
14. Treatment with any anti-diabetic medication other than insulin within 4 weeks of enrolment
15. Diabetic retinopathy
16. Arterial hypertension
17. Presence or history of macroalbuminuria
18. For female subjects older than 15 years positive pregnancy test, unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation, when appropriate
19. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation when appropriate
20. Excessive anxiety of the patient or parents related to the procedures
21. Any medical condition that, in the opinion of the investigator, will interfere with safe participation in the trial
22. For parents and children older than 15 years: known active alcohol or substance abuse

**Date of first enrolment**

02/06/2015

**Date of final enrolment**

20/09/2017

## **Locations**

**Countries of recruitment**

Poland

**Study participating centre**

**Klinika Pediatrii, Diabetologii i Endokrynologii, Uniwersyteckie Centrum Kliniczne w Gdańsku**

ul. Dębinki 7

Gdańsk

Poland

80-211

**Study participating centre**

**Klinika Pediatrii Endokrynologii Diabetologii z Pododdziałem Kardiologii, Uniwersytet Medyczny w Białymstoku**

Ul. Waszyngtona 17

Białystok

Poland

15-274

**Study participating centre**

**Klinika Pediatrii, Onkologii, Hematologii i Diabetologii Uniwersytet Medyczny w Łodzi**

ul. Sporna 36/50

Łódź

Poland

91-738

**Study participating centre**

**Klinika Pediatrii, Endokrynologii i Diabetologii Dziecięcej Górnośląskie Centrum Zdrowia Dziecka im. Jana Pawła II Śląski Uniwersytet Medyczny**

ul. Medyków 16

Katowice

Poland

40-752



# Sponsor information

## Organisation

Gdańsk Medical University

## Sponsor details

Skłodowskiej-Curie 3a

Gdańsk

Poland

80-210

+48 (0)58 3491593

ptrzon@gumed.edu.pl

## Sponsor type

University/education

## Website

<https://gumed.edu.pl/>

## ROR

<https://ror.org/019sbgd69>

## Organisation

Poltreg S.A.

## Sponsor details

Waly Piastowskie 1 Street, lok. 1508

Gdańsk

Poland

80-855

+48 (0)512532401

p.trzonkowski@poltreg.tech

## Sponsor type

Industry

## Website

<http://www.poltreg.tech>

# Funder(s)

## Funder type

Government

**Funder Name**

Narodowe Centrum Badań i Rozwoju

**Alternative Name(s)**

National Centre for Research and Development, The National Centre for Research and Development, Polish National Center for Research and Development, National Center for Research & Development, NCBR, NCBiR, NCRD

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

Poland

**Funder Name**

Horizon 2020 Framework Programme

**Alternative Name(s)**

EU Framework Programme for Research and Innovation H2020, Horizon 2020, Rahmenprogramm Horizont 2020, Programa Marco Horizonte 2020, Programme-cadre Horizon 2020, Programma quadro Orizzonte 2020, Program ramowy Horyzont 2020, Horizont 2020, Horizonte 2020, Orizzonte 2020, Horyzont 2020, Horizon 2020 Framework Programme (H2020), H2020

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

## Results and Publications

**Publication and dissemination plan**

Planned publication in a high-impact peer-reviewed journal

**Intention to publish date**

01/06/2021

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study will be stored in the NIDDK Central Repository website. The data will be fully anonymized and access will be available according to the rules of the NIDDK Central Repository.

## IPD sharing plan summary

Stored in repository

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol file</a>	version 1.0	19/04/2022	04/02/2021	No	No
<a href="#">Abstract results</a>			21/04/2022	No	No
<a href="#">Other unpublished results</a>		18/11/2020	05/05/2022	No	No
<a href="#">Other unpublished results</a>	Integrated data analysis	18/11/2020	05/05/2022	No	No